Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2023-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk for pancreatitis and development of precancerous lesions.

The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DP-b99 in the Treatment of Acute High-risk Pancreatitis

NCT02025049

Pancreatitis

TERMINATED PHASE2

Pancreatic Enzyme Suppletion in Pancreatic Cancer

NCT01401387

Adenocarcinoma of the Pancreas Normal Pancreatic Exocrine Function

WITHDRAWN PHASE4

Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

NCT06121622

Pancreatic Neuroendocrine Tumor

RECRUITING

Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy

NCT05480241

Acute Pancreatitis Exocrine Pancreatic Insufficiency Gut Microbiota +1 more

UNKNOWN NA

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744

Pancreatic Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The incretinomimetics and the inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. The incretinomimetics are analogs of Glucagon Like Peptide 1 (GLP-1), secreted from endocrine L-cells of the colon and terminal ileum peptide. Serum GLP-1 increase rapidly after a meal. But its degradation is also fast. It acts on the hypothalamus by reducing appetite and food intake, on the stomach by delaying gastric emptying and the level of beta islet cells by inducing the synthesis and secretion of insulin (1). The incretinomimetics currently marketed in Belgium (March 2014) are exenatide (Byetta ®), liraglutide (Victoza ®), lixisenatide (Lyxumia ®) and very soon (April 2014) extended-release exenatide (Bydureon ®). The DPP-4 prevent the degradation of GLP-1. The DPP-4 currently marketed (March 2014) are sitagliptin (Januvia ®), vildagliptin (Galvus ®), saxagliptin (Onglyza ®) and (Trajenta ®) linagliptin.

In diabetic patients, these treatments allow a significant reduction in fasting plasma glucose and postprandial, with a low risk of hypoglycemia and no weight gain (and sometimes weight loss) (2).

Their place in the management of type 2 diabetes is considered or in combination with metformin, when diabetes is inadequately controlled despite maximal dose of the latter, or when patients are intolerant to metformin.

A study to evaluate the safety of 'incretinomimetics therapy "showed an increase in pancreatic weight of 40% (3). Indeed, in a cohort of 34 pancreatic organ donors from brain death, 20 patients were diabetic and 8 as incretin mimetics for over 1 year. An increase in pancreatic mass on average 40% was observed compared to diabetic patients without this treatment.

This study also demonstrated an increase in the mass of beta cells without restoring insulin function. The advanced for this mass increase without a significant increase of cell size is a hypothesis decreased apoptosis of beta cells.

Furthermore there is also an increase in the mass of cells producing α intraductulaire cell proliferation. This would be responsible for the onset of pancreatitis but also the appearance of endocrine microadenomas. The same study (3) also observed an increase in cell proliferation in the exocrine compartment of the pancreas (ductal and acinar cells) induced by incretinomimetic and an increased frequency of lesions potentially pre-cancerous PanIN 1 and 2 with this treatment.

Another study (4) by the same group of researchers showed that GLP-1 induced ductal cell growth in rats treated with high-dose exenatide for 12 weeks. It could therefore, by ductal obstruction induce pancreatitis.

All of these studies therefore warns about these new treatments potentially inducers of different pancreatic lesions.

The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Incretinomimetics Pancreas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sulfonylurea

Patient will received metformine with sulfonylurea

Group Type ACTIVE_COMPARATOR

Incretinomimetics

Intervention Type DRUG

DPP-4 inhibitors

Intervention Type DRUG

Incretinomimectics

Patients will received metformin with sulfonylurea with GLP-1 analogue

Group Type ACTIVE_COMPARATOR

DPP-4 inhibitors

Intervention Type DRUG

DPP-4 inhibitors

Patients will received metformin with DPP-4 inhibitors

Group Type ACTIVE_COMPARATOR

Incretinomimetics

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Incretinomimetics

Intervention Type DRUG

DPP-4 inhibitors

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

- exenatide (Byetta®) - liraglutide (Victoza®) - lixisenatide (Lyxumia®) - exenatide extended-release (Bydureon®). - sitagliptine (Januvia®) - vildagliptine (Galvus®) - saxagliptine (Onglyza®) - linagliptine (Trajenta®).

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes inadequately controlled or intolerant to metformin
* Obtaining informed consent
* Aged between 18 and 70 years
* BMI between 20 and 45 kg / m²

Exclusion Criteria

* Contraindication to nuclear magnetic resonance (NMR):
* Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)
* Allergy to Gadolinium / Secretin
* Pregnancy or breastfeeding
* Contraindication to treatment with incretinomimetic:
* Hypersensitivity to the active substance or to any of the excipients
* Severe Gastroparesis
* Severe renal impairment
* History of Surgery (gastroduodenal, pancreatic or ileocecal)
* Presence or history of pancreatic disease
* Active alcoholism

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No